Cardiogeni (AQSE:CGNI) FCF Margin %: 0.00% (As of . 20)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Cardiogeni FCF Margin %?

Cardiogeni AQSE:CGNI FCF Margin % is 0.00% as of . 20.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Cardiogeni's Free Cash Flow for the six months ended in . 20 was £0.00 Mil. Cardiogeni's Revenue for the six months ended in . 20 was £0.00 Mil. Therefore, Cardiogeni's FCF Margin % for the quarter that ended in . 20 was 0.00%.

As of today, Cardiogeni's current FCF Yield % is 0.00%.

The historical rank and industry rank for Cardiogeni's FCF Margin % or its related term are showing as below:


AQSE:CGNI's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -76.29
* Ranked among companies with meaningful FCF Margin % only.

Cardiogeni FCF Margin % Related Terms

Cardiogeni FCF Margin % Historical Data

* Premium members only.

The historical data trend for Cardiogeni's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cardiogeni FCF Margin % Chart

Cardiogeni Annual Data
Trend
FCF Margin %

Cardiogeni Semi-Annual Data
FCF Margin %

AQSE:CGNI vs : FCF Margin % Comparison

For the Biotechnology subindustry, Cardiogeni's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiogeni FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiogeni's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Cardiogeni's FCF Margin % falls into.


Cardiogeni FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Cardiogeni's FCF Margin for the fiscal year that ended in . 20 is calculated as

FCF Margin=Free Cash Flow (A: . 20 )/Revenue (A: . 20 )
=/
= %

Cardiogeni's FCF Margin for the quarter that ended in . 20 is calculated as

FCF Margin=Free Cash Flow (Q: . 20 )/Revenue (Q: . 20 )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Cardiogeni (AQSE:CGNI) has a FCF Margin % of 0.00% as of . 20. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cardiogeni and its competitors.
Is Cardiogeni's FCF Margin % too high?
Cardiogeni's current FCF Margin % is 0.00%.
How does Cardiogeni's FCF Margin % compare to ?
Cardiogeni's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Cardiogeni and its competitors. Cardiogeni's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cardiogeni stock overvalued right now?
Cardiogeni (AQSE:CGNI) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Cardiogeni (AQSE:CGNI), the current FCF Margin % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cardiogeni Business Description

Comparable Companies
Address Celixir House Stratford-Upon-Avon Business & Technology Park, Innovation Way, Stratford upon Avon, GBR, CV37 7GZ
Cardiogeni PLC is engaged in the development and commercialisation of a portfolio of novel cellular medicines for heart failure. The Company focuses on the development and commercialisation of novel cellular medicines targeting early- and mid-stage heart failure. Its strategic priority is to complete a pivotal Phase 2b/3 study and obtain first market approval for its product, CLXR-001, in a suitable jurisdiction, and then establish strategic funding and collaboration agreements to develop and commercialise the product in the US, EU, Japan, and other jurisdictions.